We additionally investigated the association of the different patient sub-populations, given by the Ang-2 and KRAS patient stratification, with best overall response (assessed according to Response Evaluation Criteria in Solid Tumours [RECIST] 1.1 criteria) and observed that a greater number of patients responded to vanucizumab than to bevacizumab in the KRAS wild-type high Ang-2 population, which also suggests that this subpopulation benefits more from the dual inhibition of Ang-2 and VEGF-A. Here, KRAS is linked to neoplasm.